Loading…
← CockpitCompetitor Analysis › 7780.TW Daiken Biomedical Co., Ltd.Open in the cockpit ↗

Daiken Biomedical Co., Ltd.7780.TWCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Other
Momentum neutral 49
Mkt cap
$342M
US dollars, full cap
$/day
$418,343
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
+46.7 pp
WACC 5.0%
Hurdle
n/a
no reverse DCF
Next earnings
113 days
11 Mar 2027
Close · TWDNT$14.50
1D-1.4%
1W-4.0%
1M-9.7%
3M-12.7%
6M-19.0%
YTD-19.2%
1Y-16.9%
ATR %2.6%
52w lowhigh50.7% off high

What Daiken Biomedical does

Employees: 58

Daiken Biomedical at a glance

Size Daiken Biomedical (7780.TW) is a Taiwan Health Care company (Pharmaceuticals: Other) with a market value of $342M, the 577th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$14.50 on 18 Nov 2026.

Performance Over six months the shares fell 19.0%, against -22.3% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th highest of 21 in its peer set.

Growth The operating margin is 17.8% (peer median 8.5%).

Valuation It trades at 3.0× enterprise value to sales against a peer median of 2.2× (9th most expensive of 20).

Capital Return on invested capital runs 46.7 points above its cost of capital (5.0% WACC).

Next results Next results expected around 11 Mar 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 20267780.TW 79Peer median 78
Six months, rebased to 100: Daiken Biomedical against the median of its 20 peers (local-currency closes).

Daiken Biomedical financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025
RevenueNT$2.34BNT$1.90B
Revenue growth——
Gross profitNT$1.43BNT$1.21B
EBITDANT$425MNT$295M
Net incomeNT$468MNT$338M
Free cash flowNT$207MNT$270M
Capital expenditureNT$322MNT$5.16M
Total debtNT$17.0MNT$123M

Quarterly statements and history in the cockpit →

Daiken Biomedical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-30%-20%-10%0%-20%0%1707BOI3005198436603102317450603669002412002644AVBP077500256230003960048830079128777780.TW6-month return →1-month return →
Up and to the right = strong over both horizons. Daiken Biomedical is the large dot.

Daiken Biomedical competitors and peer comparison

How Daiken Biomedical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Daiken Biomedical against its 20 peers (data as of 18 Nov 2026)
Measure7780.TWPeer medianRank in peer set
1-month return-9.7%-11.4%8th highest of 21
6-month return-19.0%-22.3%7th highest of 21
Distance from 52-week high-50.7%-41.8%3rd lowest of 21
Operating margin17.8%8.5%8th highest of 21
EV / Sales3.0×2.2×9th most expensive of 20
Growth the price implies (Req g, 7 yrs)-1.6%1.4%4th least demanding of 14
ROIC minus cost of capital+46.7 pp-0.1 pp2nd highest of 20
EV / EBITDA16.5×4.6×most expensive of 5
Net debt / EBITDA-10.1×-1.3×least indebted of 7

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Daiken Biomedical 7780.TWTaiwan$342M-19%n/a18%3.0×-1.6%n/a
Grape King Bio 1707.TWTaiwan$342M-27%-5%19%1.0×-17.2%+2.3%
Boiron BOI.PAFrance$367M-31%-2%5%0.6×-0.8%-0.5%
Zhejiang Xinguang Pharmaceutical 300519.SZChina$319M-15%+5%27%5.1×3.1%-1.3%
TCI 8436.TWOTaiwan$312M-24%-4%18%1.3×-12.1%-3.2%
Weihai Baihe Biology Technological 603102.SSChina$296M-22%+18%14%0.9×-11.8%+9.6%
Tibet Aim Pharm 002826.SZChina$407M-22%+13%14%2.9×0.4%+1.0%
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%0.7×n/an/a
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%8.4×n/an/a
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%3.0×1.4%+7.0%
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%3.3×15.4%+6.5%
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%34.2×n/an/a
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%3.8×19.1%+12.1%
ABA Chemicals 300261.SZChina$592M-26%-16%-23%4.9×n/an/a
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%2.0×n/an/a
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%1.8×n/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%1.5×4.0%+13.5%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%3.4×0.4%+4.8%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%2.2×2.1%-1.3%
Sirio Pharma 300791.SZChina$759M-6%-9%1%1.5×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%n/an/an/a

Questions

Which companies are Daiken Biomedical's closest peers?
The cockpit's peer set: Grape King Bio (1707.TW), Boiron (BOI.PA), Zhejiang Xinguang Pharmaceutical (300519.SZ), TCI (8436.TWO), Weihai Baihe Biology Technological (603102.SS), Tibet Aim Pharm (002826.SZ), Myung in Pharm (317450.KS), Lionco Pharmaceutical (603669.SS).
Is Daiken Biomedical expensive compared with its peers?
On ev / sales it trades at 3.0× against a peer median of 2.2×, 9th most expensive of 20 in its peer set.
How has Daiken Biomedical stock performed?
Over six months to 18 Nov 2026 the shares returned -19.0% against -22.3% for the median peer; over one year -16.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.